

SEQ ID NO:3 aligned with Biogen's SEQ ID NO:3

```

<!--StartFragment-->RESULT 1
AAB60699
ID  AAB60699 standard; protein; 302 AA.
XX
AC  AAB60699;
XX
DT  11-SEP-2003 (revised)
DT  22-MAY-2001 (first entry)
XX
DE  Mouse IgG signal/human BAFF-R/human IgG Fc fusion protein, BAFF-R-Fc.
XX
KW  Human BAFF-R; BAFF receptor; TNF family; immunoregulatory agent;
KW  immune-related disorder; B-cell growth inhibitor;
KW  B-cell maturation inhibitor; immunoglobulin production inhibitor;
KW  autoimmune disorder; B-cell lymphoproliferative disorder; hypertension;
KW  renal disorder; immunosuppressive disorder; HIV infection;
KW  organ transplantation; antiinflammatory; systemic lupus erythematosus;
KW  autoimmune haemolytic anaemia; Grave's disease; multiple myeloma;
KW  B-cell carcinoma; leukaemia; rapidly progressive glomerulonephritis;
KW  lymphoma; gene therapy; cancer; tumour; IgG Fc; fusion construct.
XX
OS  Homo sapiens.
OS  Mus sp.
OS  Chimeric.
XX
PN  WO200112812-A2.
XX
PD  22-FEB-2001.
XX
PF  16-AUG-2000; 2000WO-US022507.
XX
PR  17-AUG-1999; 99US-0149378P.
PR  11-FEB-2000; 2000US-0181684P.
PR  18-FEB-2000; 2000US-0183536P.
XX
PA  (BIOJ ) BIOGEN INC.
PA  (APOT-) APOTEC R & D SA.
XX
PI  Mackay F, Browning J, Ambrose C, Tschopp J, Schneider P;
PI  Thompson J;
XX
DR  WPI; 2001-202866/20.
DR  N-PSDB; AAF59999.
XX
PT  Inhibiting dendritic cell-induced B-cell growth, maturation and B-cell
PT  lympho-proliferative disorder by administering BAFF-receptor polypeptide,
PT  chimeric molecule comprising receptor or anti-BAFF-R antibody homolog.
XX
PS  Example 4; Fig 2; 59pp; English.
XX
CC  The invention relates to the use of a BAFF receptor (BAFF-R, also known
CC  as BCMA) protein, or a BAFF-R fusion protein as an agent for the
CC  treatment of a variety of immune-related disorders. BAFF-R is a member of
CC  the TNF (tumour necrosis factor) family, acting as an immunoregulatory
CC  agent, and also plays a role in the development of hypertension and
CC  related disorders. BAFF-R, fusion proteins containing it, and BAFF-R-
CC  specific antibodies can be used for inhibiting B-cell growth, dendritic
CC  cell-induced B-cell growth and maturation, and immunoglobulin production,
CC  and in the treatment of autoimmune disorders, B-cell lymphoproliferative
CC  disorders, hypertension and renal disorders. The BAFF-R proteins may also
CC  be used in the treatment of immunosuppressive disorders and HIV

```

CC infection, and in patients undergoing organ transplantation. The BAFF-R
CC proteins or BAFF-R specific antibodies may be used for treating,
CC suppressing or altering an immune response involving a signalling pathway
CC between BAFF-R and BAFF, thereby inhibiting inflammation. Since BAFF-R
CC inhibits B-cell growth and maturation it is useful for treating diseases
CC such as systemic lupus erythematosus, autoimmune haemolytic anaemia,
CC Grave's disease, multiple myeloma, B-cell carcinomas, leukaemia, rapidly
CC progressive glomerulonephritis, and lymphomas. Nucleic acids encoding
CC human BAFF-R may be used in gene therapy to treat tumours, lymphomas,
CC autoimmune disorders and inherited B-cell-associated disorders. The
CC present sequence represents the BAFF-R fusion protein BAFF-R-Fc,
CC comprising a mouse IgG-kappa signal sequence, residues 1-153 of human
CC BAFF-R and a human IgG Fc sequence. (Updated on 11-SEP-2003 to
CC standardise OS field)
XX
SQ Sequence 302 AA;

Query Match 100.0%; Score 1643; DB 4; Length 302;
Best Local Similarity 100.0%; Pred. No. 6.4e-112;
Matches 302; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 METDTLLLVLLLWVPGSTGDVTMLQMAGQCSQNEYFDSLHACIPCQLRCSSNTPPLTC 60
|
Db 1 METDTLLLVLLLWVPGSTGDVTMLQMAGQCSQNEYFDSLHACIPCQLRCSSNTPPLTC 60

Qy 61 QRYCNASVTNSVKGVDKTHTCPPCPAPPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD 120
|
Db 61 QRYCNASVTNSVKGVDKTHTCPPCPAPPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD 120

Qy 121 VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN 180
|
Db 121 VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN 180

Qy 181 KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNG 240
|
Db 181 KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNG 240

Qy 241 QPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNVFSQSVMEALHNHYTQKSLSLSP 300
|
Db 241 QPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNVFSQSVMEALHNHYTQKSLSLSP 300

Qy 301 GK 302
||
Db 301 GK 302
<!--EndFragment-->